Absci partners with AMD, investing $20 million to enhance AI-driven drug discovery and antibody design capabilities.

--Absci Corporation, a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power ...

Advanced Micro Devices is investing $20 million in Absci, a drug-discovery company based in Washington state, in a move aimed at selling its artificial intelligence chips in the healthcare sector ...

AMD’s support will enable Absci to enhance its proprietary antibody design model, IgDesign1, which is the first in vitro validated inverse folding model for antibody design.

Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. See why I think ABSI stock is a good buy.

VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (ABSI) (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to ...

Advanced Micro Devices is investing $20 million in Absci, a drug-discovery company based in Washington state, in a move aimed at selling its artificial intelligence chips in the healthcare sector.

Absci shares are rising after announcing a strategic collaboration with Advanced Micro Devices Inc. The partnership will enhance Absci's AI drug discovery capabilities using AMD Instinct ...

Absci can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and furthermore, actual results may differ materially from those described in the ...

Absci and AMD will showcase the exceptional performance of AMD’s Instinct accelerators in addressing complex biological applications, including Absci’s proprietary IgDesign1 model, the first ...